• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Emerg Infect Dis . Incorporating COVID-19 into Acute Febrile Illness Surveillance Systems, Belize, Kenya, Ethiopia, Peru, and Liberia, 2020-2021

tetano

Editor, Senior Moderator
Emerg Infect Dis


. 2022;28(13):34-41.
doi: 10.3201/eid2813.220898.
Incorporating COVID-19 into Acute Febrile Illness Surveillance Systems, Belize, Kenya, Ethiopia, Peru, and Liberia, 2020-2021

David C Shih, Rachel Silver, Olga L Henao, Aynalem Alemu, Allan Audi, Godfrey Bigogo, Josh M Colston, Elijah P Edu-Quansah, Timothy A Erickson, Andargachew Gashu, G Burgess Gbelee Jr, Sarah M Gunter, Margaret N Kosek, Gorbee G Logan, Joy M Mackey, Adrianna Maliga, Russell Manzanero, Gerhaldine Morazan, Francis Morey, Flor M Munoz, Kristy O Murray, Thelma V Nelson, Maribel Paredes Olortegui, Pablo Penataro Yori, Shannon E Ronca, Francesca Schiaffino, Adamu Tayachew, Musse Tedasse, Mesfin Wossen, Denise R Allen, Pawan Angra, Amanda Balish, Madeline Farron, Marta Guerra, Amy Herman-Roloff, Victoria J Hicks, Elizabeth Hunsperger, Lilit Kazazian, Matt Mikoleit, Peninah Munyua, Patrick K Munywoki, Angella Sandra Namwase, Clayton O Onyango, Michael Park, Leonard F Peruski, David E Sugerman, Emily Zielinski Gutierrez, Adam L Cohen

Abstract

Existing acute febrile illness (AFI) surveillance systems can be leveraged to identify and characterize emerging pathogens, such as SARS-CoV-2, which causes COVID-19. The US Centers for Disease Control and Prevention collaborated with ministries of health and implementing partners in Belize, Ethiopia, Kenya, Liberia, and Peru to adapt AFI surveillance systems to generate COVID-19 response information. Staff at sentinel sites collected epidemiologic data from persons meeting AFI criteria and specimens for SARS-CoV-2 testing. A total of 5,501 patients with AFI were enrolled during March 2020-October 2021; >69% underwent SARS-CoV-2 testing. Percentage positivity for SARS-CoV-2 ranged from 4% (87/2,151, Kenya) to 19% (22/115, Ethiopia). We show SARS-CoV-2 testing was successfully integrated into AFI surveillance in 5 low- to middle-income countries to detect COVID-19 within AFI care-seeking populations. AFI surveillance systems can be used to build capacity to detect and respond to both emerging and endemic infectious disease threats.

Keywords: Belize; COVID-19; Ethiopia; Kenya; Liberia; Peru; SARS; SARS-CoV-2; acute disease; coronavirus; coronavirus disease; epidemiology; fever; global health; incidence; respiratory infections; sentinel surveillance; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.
 
Back
Top Bottom